Elanco Says Pet Spending Is a "Protected Budget Item." The Number Behind That Claim Is 7%.

Pet owners aren't trading down. Ninety-one percent of them held or grew their spend on pet health and wellness through the recent inflation cycle, with 38% spending more. That data point, released by Elanco on June 3, is the most useful new number in the resilience story since APPA's 2026 forecast — and it lands with a 7% industry growth print for 2025 attached.

Elanco data: 91% of pet owners hold or grow health spend

Elanco Animal Health (NYSE: ELAN) released consumer research this morning showing pet owners are continuing to prioritize pet health and wellness spend despite higher household costs. The survey of 1,409 U.S. pet owners, fielded May 29 to 31, found 91% maintained or increased their spend on pet health and wellness in recent years. Of that group, 38% spent more.

Eighty-eight percent of pet parents said their pet's happiness and wellbeing is as important as their own.

The release ties the consumer behavior to category economics. Elanco notes the animal health industry has averaged roughly 5% annual growth over the past two decades and estimates the industry expanded by 7% in 2025. The company projects the global animal health market grows from $42 billion in 2025 to $60 billion over the next decade, roughly a 3.6% CAGR if measured to a $60B endpoint, though the 7% near-term print runs hot of that long-run rate.

The survey lands a month after Elanco's Q1 2026 print, where pet health revenue reached $710 million, up 12% reported and 7% organic constant currency. Total Elanco revenue grew 15% reported in Q1, and management raised full-year guidance to $5.01–$5.09 billion. The company has now had two consecutive quarters of mid-single-digit organic pet-health growth, anchored by Zenrelia hitting trailing four-quarter blockbuster status and the early launch of Befrena, its second USDA-approved pet biologic and first real Cytopoint competitor in eight years, in the $1.3 billion U.S. canine dermatology market.

The research itself is not novel methodologically. What's notable is who paid for it, and when.

Why animal health is now pricing in 7% growth as the new floor

The 5% historical growth rate for animal health has been the industry's North Star for a decade. Every investor deck, every M&A pitch, every public-company guidance frame has rested on roughly 5% as the gravity-defining floor of the category. Elanco just put a 7% number on the table and is asking the market to treat it as the new floor.

The case for 7% sticking is the strongest it has been since the post-pandemic snap-back.

The APPA's 2026 State of the Industry report pegged total U.S. pet expenditures at $158 billion in 2025 with a $165 billion 2026 projection. That's a 3.7% print for 2025 and a 4.4% projection for 2026 — roughly 2% of which APPA attributes to inflation. Animal health, the slice Elanco is measuring, grows faster than the broader $158B figure because pet ownership is shifting up the price ladder in clinical and wellness categories.

The dog ownership base alone grew from 51% of U.S. households in 2024 to 53% in 2025, an addition of roughly 4 million dog-owning households year over year. That's the demand-side fuel. The supply-side fuel is a wave of newly approved pet biologics — Befrena, Zenrelia, and a coming class of monoclonal antibodies for canine and feline indications — that carry higher gross margins than the historical parasiticide-and-vaccine mix.

What Elanco is doing with this release is brand positioning more than market research. The company spent the past 18 months trying to convert from a slower-growing animal health holding company into a pet-health innovation story. The Q1 print, the Befrena launch, and now a survey explicitly framing pet wellness spend as a "protected budget item" are pieces of the same narrative campaign. Each piece reinforces the others when the company sits down with sell-side analysts.

The implication for operators sits on three levels.

For premium pet-product brands, the 38% "spent more" segment is the real signal. That's the cohort defending price increases and absorbing premium SKU launches. Brands that hesitated on 2026 price hikes have cover to take them now.

For retailers, the resilience thesis is increasingly consensus, which means it's increasingly priced in. Tractor Supply's vertical-integration push into vet care via the VIP Petcare deal, Chewy's autoship-led margin story, and Petco's wellness re-platforming all hinge on owners holding the line on care spend. This data validates the strategy. It also raises the bar for execution — if the macro tailwind is consensus, the relative winner is the operator with the best conversion and retention mechanics, not the best demand-side bet.

For animal-health peers — Zoetis, Boehringer Ingelheim, Merck Animal Health, Virbac — the 7% growth claim is a benchmarking event. Either they confirm it on their own earnings calls or they introduce a competing growth narrative. Zoetis has historically positioned itself as the franchise leader in companion-animal therapeutics, but its Q1 print landed flat with U.S. companion animal slipping 11% — making Elanco's "protected budget" framing more uncomfortable to leave unanswered. If Elanco keeps pulling the consumer-data lever to define the category, Zoetis will need to respond with its own framing within a quarter.

The data point that didn't make it into the release: how much of the 38% "spent more" cohort is volume versus mix versus price. If the increase is primarily price-driven, the resilience thesis is more fragile than it looks. If it's mix — owners moving from generic to brand or from over-the-counter to prescription — the runway is real. Elanco knows the answer. The release doesn't disclose it.

What Q2 earnings will reveal about the 7% claim

Three windows close in the next 90 days, each of which validates or undermines the 7% number.

Zoetis Q2 earnings (early August): Zoetis reports Companion Animal as its own segment, the cleanest read on whether the category is growing 7% or whether Elanco's print is a portfolio-specific outperformance. If Zoetis CA growth is materially below 7%, Elanco's number is talking its own book.

Chewy Q1 results (June 10): Chewy's healthcare and wellness disclosure will show whether consumer behavior is matching the survey claim. The autoship attach rate in vet care and Rx — already the load-bearing piece of Chewy's FY2026 guidance raise — is the cleanest leading indicator.

APPA mid-year refresh: APPA typically publishes interim category breakdowns through the summer. A re-rate of the 2026 $165B projection upward would confirm Elanco's framing as industry consensus rather than self-interested signaling.

The pricing-versus-volume question: Any animal-health analyst worth her seat will press Zoetis and Elanco on the call to break out the mix. The first one that answers cleanly resets the category's growth narrative.

The "protected budget" framing itself: Watch whether competitors adopt it, push back on it, or counter-position with their own consumer-data play. Industry framings stick when peers borrow them and break when peers reject them.

If the 7% number holds through Q2 earnings season, animal-health multiples re-rate. If it doesn't, the "protected budget" framing gets retired, and the category settles back into its 5% long-run baseline. Either way, the next 90 days decide how the rest of 2026 gets priced.

Source: Elanco via PR Newswire